These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 8978998)

  • 1. Mycophenolate mofetil in kidney transplantation.
    Lui SL; Halloran PF
    Curr Opin Nephrol Hypertens; 1996 Nov; 5(6):508-13. PubMed ID: 8978998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
    Sollinger HW
    Transplantation; 1995 Aug; 60(3):225-32. PubMed ID: 7645033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection.
    Simmons WD; Rayhill SC; Sollinger HW
    Drug Saf; 1997 Aug; 17(2):75-92. PubMed ID: 9285199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation.
    Fulton B; Markham A
    Drugs; 1996 Feb; 51(2):278-98. PubMed ID: 8808168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of clinical experience with the novel immunosuppressive drug mycophenolate mofetil in renal transplantation.
    Behrend M
    Clin Nephrol; 1996 May; 45(5):336-41. PubMed ID: 8738667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial.
    Remuzzi G; Lesti M; Gotti E; Ganeva M; Dimitrov BD; Ene-Iordache B; Gherardi G; Donati D; Salvadori M; Sandrini S; Valente U; Segoloni G; Mourad G; Federico S; Rigotti P; Sparacino V; Bosmans JL; Perico N; Ruggenenti P
    Lancet; 2004 Aug 7-13; 364(9433):503-12. PubMed ID: 15302193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of Mycophenolate Mofetil (Cellcept) in renal transplantation.
    Vanrenterghem Y
    Nephron; 1997; 76(4):392-9. PubMed ID: 9274835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycophenolate mofetil--is it worth the cost? The in-favor opinion.
    Seikaly MG
    Pediatr Transplant; 1999 Feb; 3(1):79-82. PubMed ID: 10359036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost effectiveness of mycophenolate mofetil in the first year after primary cadaveric transplant. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
    Sullivan SD; Garrison LP; Best JH
    J Am Soc Nephrol; 1997 Oct; 8(10):1592-8. PubMed ID: 9335389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolate mofetil for maintenance therapy in kidney transplantation.
    Gonwa TA
    Clin Transplant; 1996 Feb; 10(1 Pt 2):128-30. PubMed ID: 8680049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A placebo controlled study of mycophenolate mofetil used in combination with cyclosporine and corticosteroids for the prevention of acute rejection in renal allograft recipients: 1-year results. The European Mycophenolate Mofetil Cooperative Study Group.
    Wiesel M; Carl S
    J Urol; 1998 Jan; 159(1):28-33. PubMed ID: 9400430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolate mofetil: suggested guidelines for use in kidney transplantation.
    Behrend M
    BioDrugs; 2001; 15(1):37-53. PubMed ID: 11437674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate mofetil.
    Sievers TM; Rossi SJ; Ghobrial RM; Arriola E; Nishimura P; Kawano M; Holt CD
    Pharmacotherapy; 1997; 17(6):1178-97. PubMed ID: 9399601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of mycophenolate mofetil in kidney transplantation].
    Hrvacevic R; Ignjatovic Lj; Vavic N
    Vojnosanit Pregl; 2001; 58(4):415-9. PubMed ID: 11712223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced kidney transplant rejection rate and pharmacoeconomic advantage of mycophenolate mofetil.
    Wüthrich RP; Weinreich T; Ambühl PM; Schwarzkopf AK; Candinas D; Binswanger U
    Nephrol Dial Transplant; 1999 Feb; 14(2):394-9. PubMed ID: 10069195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mycophenolate mofetil, a possible new immunosuppresant].
    Weberová J; Voboril R; Semecký V
    Ceska Slov Farm; 2002 Sep; 51(5):220-5. PubMed ID: 12407919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic impact and long-term graft outcomes of mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant recipients.
    Machnicki G; Ricci JF; Brennan DC; Schnitzler MA
    Pharmacoeconomics; 2008; 26(11):951-67. PubMed ID: 18850764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolate mofetil for the transplanted kidney?
    Drug Ther Bull; 1997 May; 35(5):38-40. PubMed ID: 9282420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate mofetil, along with ATG and cyclosporine, significantly lowers the incidence of acute rejection episodes in renal transplant recipients.
    Puig JM; Lloveras J; Fernández-Crespo P; Mir M; Iñigo V; Manresa JM; Masramón J
    Transplant Proc; 1999 Sep; 31(6):2259-60. PubMed ID: 10500567
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.